We previously found a positive correlation between Rb expression levels and the activity of ribociclib in SCCHN preclinical models, providing a possible explanation for the limited antitumoral effect of ribociclib in combination with cetuximab in these cetuximab-resistant models [20]. The gene discussed is RB1; the disease is head and neck squamous cell carcinoma.